We also observed that ULBP2 expression is increased in HPV16-positive precancers as compared to HPV31-positive precancers, indicating that HPV16-positive precancers are more robust at evading immunosurveillance and, therefore more likely to progress to cancer than HPV31-positive precancers. Here, ULBP2 is linked to cancer.